Obviousness — US Patent 7670612

Obviousness Analysis of US Patent 7,670,612 under 35 U.S.C. § 103

Based on the prior art of record, the independent claims of US patent 7,670,612 are highly vulnerable to a challenge of obviousness under 35 U.S.C. § 103. An invention is considered obvious if the differences between the claimed invention and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art (POSA).

A POSA in this context would be a pharmaceutical formulation scientist or engineer circa 2002-2004 with experience in designing oral dosage forms, including capsules, and knowledge of formulating active ingredients such as pharmaceuticals, vitamins, and dietary supplements.

Analysis of Independent Claim 1

Claim 1 recites: A multi-compartment capsule comprising:

(a) At least two receiving chambers.
(b) A first ingredient in a first chamber, where the ingredient is a nutraceutical, vitamin, dietary supplement, or mineral, and is in a first physical state (e.g., solid, liquid, gas).
(c) A second ingredient in a second chamber, where the ingredient is also a nutraceutical, vitamin, dietary supplement, or mineral, and is in a second, different physical state.

The following combinations of prior art would render the claimed subject matter of Claim 1 obvious.

1. U.S. Patent 6,482,434 (Lledo) on its own or as a Primary Reference

U.S. Patent 6,482,434 (Lledo) is exceptionally strong prior art that arguably anticipates, and at a minimum renders obvious, Claim 1.

Lledo's Teachings: As described in the prior art analysis, Lledo explicitly discloses a "two compartment capsule" to solve the problem of stabilizing the dietary supplement SAMe. Crucially, Lledo teaches filling one compartment with a solid tablet of SAMe (a dietary supplement) and the other compartment with a liquid or semi-solid containing a second ingredient, such as a vitamin and/or a mineral.
Obviousness Argument: Lledo teaches every element of Claim 1. It discloses a capsule with two chambers, containing ingredients from the precise classes recited in Claim 1 (dietary supplement, vitamin, mineral) in two different physical states (solid and liquid). A POSA would find it entirely obvious to substitute the specific ingredients in Lledo (SAMe, vitamins, minerals) with any other ingredients from the same disclosed classes (nutraceuticals, vitamins, dietary supplements, minerals) to solve the same known problem of combining incompatible substances or improving consumer convenience. Lledo provides the complete blueprint and motivation for the invention claimed in the '612 patent.

2. Combination of U.S. Patent 6,214,376 (De-Vriendt) and U.S. Patent 6,482,434 (Lledo)

This combination provides a compelling argument for obviousness.

Base Reference (De-Vriendt): De-Vriendt establishes the foundational technology. It teaches a soft gelatin capsule with at least two compartments designed to hold different, potentially incompatible fill materials. De-Vriendt explicitly states that one fill material can be a liquid and the other can be a solid. It further identifies vitamins as a possible fill material.
Motivation to Combine/Modify: A POSA starting with De-Vriendt's general concept of a multi-phase, multi-compartment capsule for vitamins would be motivated to look for specific applications of this technology within the field of nutritional products. Lledo provides just such an application. A POSA would see that the known technology of separating liquid and solid phases, as taught by De-Vriendt, could be directly applied to solve the specific stability and co-delivery problems for the exact classes of compounds mentioned in Lledo—dietary supplements, vitamins, and minerals. The motivation to combine these teachings is to leverage a known delivery system (De-Vriendt) for a known category of ingredients (Lledo) to achieve a known goal (co-delivery of incompatible ingredients). This constitutes a classic case of applying a known technique to a known device ready for improvement, which is a hallmark of obviousness.

3. Combination of U.S. Patent 4,738,852 (Fraipont) or U.S. Patent 5,679,376 (Sheth) with General Knowledge in the Art

These combinations demonstrate that the core concept was broadly known and its application to supplements would have been an obvious extension.

Base References (Fraipont or Sheth): Both Fraipont and Sheth teach the fundamental structure of Claim 1: a capsule with two distinct compartments capable of holding ingredients in different physical states (e.g., liquid/pasty and solid). These patents describe the contents as "active substances," "medicaments," or "drugs."
Motivation to Combine/Modify: The only distinction between these references and Claim 1 of the '612 patent is the specific recitation of "nutraceuticals, vitamins, dietary supplements, or minerals." By the early 2000s, vitamins and dietary supplements were a massive and growing market, and formulators were constantly seeking new delivery methods to improve stability and consumer appeal. Applying the established multi-compartment capsule technology of Fraipont or Sheth to the field of dietary supplements would have been an obvious, market-driven extension. There was no technical barrier or unpredictability in doing so. A POSA would have had a reasonable expectation of success in placing a liquid vitamin and a powdered mineral into the capsule structure described by Fraipont, as the physical principles of encapsulation are not limited to one specific class of "active substance." The motivation is simply to apply a known solution to an analogous field to gain the same benefits (separation of incompatible ingredients, novel dosage forms).

Analysis of Independent Claim 11

Claim 11 recites a method of delivering the multi-compartment capsule of Claim 1 by oral administration.

Obviousness Argument: This claim is derivative of Claim 1 and is obvious for the same reasons. All the cited prior art references (De-Vriendt, Lledo, Fraipont, and Sheth) describe oral dosage forms (capsules) intended to be swallowed. Oral administration is the inherent and sole intended use of such a capsule. If the apparatus of Claim 1 is obvious based on the prior art, then the method of using that apparatus for its intended and conventional purpose—swallowing it—is also obvious. There is no non-obvious method step recited in Claim 11; it merely claims the act of using the obvious device. Therefore, any combination of prior art that renders Claim 1 obvious would likewise render Claim 11 obvious.